Center for Biologics Evaluation and Research

From Wikipedia, the free encyclopedia

The Center for Biologics Evaluation and Research (CBER) is one of five main centers for the Food and Drug Administration, which is in the United States Department of Health and Human Services. CBER is responsible for assuring the safety, purity, potency, and effectiveness of biological products such as:

Blood and blood products.
Cells and tissues for transplant.
Vaccines.
Gene therapy.^[1]

[edit] Authority

As of July 2006 CBER's authority resides in section 351 of the Public Health Service Act and in various sections of the Food, Drug and Cosmetic Act.^[2]

Please expand this article.
Further information might be found in a section of the talk page or at Requests for expansion.

At the CBER's Vaccines and Related Biological Products Advisory Committee's 101st meeting of February 16, 2005, an extensive discussion and vote was held concerning next year's flu vaccine virus selection. ^[3]

[edit] Further reading

[edit] Sources

^ CBER websit, CBER's Vision and Mission: [1]
^ CBER website, About CBER:[2]
^ (transcript of U.S. FDA Center for Biologics Evaluation and Research Vaccines and Related Biological Products Advisory Committee's 101st meeting of February 16, 2005 is here: origin.www.fda.gov in .DOC format in Google provided HTML format)